Some antidepressants could potentially be used to treat a wide range of diseases caused by bacteria living within cells, according to work by researchers in the Virginia Commonwealth University School of Medicine and collaborators at other institutions.
Research published in the April print edition of the journal Life Science Alliance, shows that antidepressant drugs called FIASMAs, including desipramine, amitriptyline, and nortriptyline, halt the growth or kill four different intracellular bacterial pathogens in tissue cell culture and animal models.
“Antibiotic options for diseases caused by intracellular bacteria are limited because many of these drugs cannot penetrate our cell membranes. In essence, the bacteria are protected,” said Jason Carlyon, Ph.D., leader of the study and professor in the VCU Department of Microbiology and Immunology.
Tetracycline antibiotics are most commonly prescribed to treat intracellular bacterial infections because they can cross cell membranes to reach the microbes. However, tetracyclines can cause allergic reactions in some patients and physicians advise against their use by pregnant women and children due to undesirable side effects. Additionally, antibiotic resistance in some intracellular bacteria has been reported.
“It would be highly beneficial to have a class of drugs to treat such diseases in patients for whom tetracyclines are contraindicated,” Carlyon said. “These drugs could provide an alternative to antibiotics or even be used in conjunction with them as an augmentation approach to treat infections that typically require prolonged courses of antibiotic therapy, such as those caused by Chlamydia pneumoniae and Coxiella burnetti.”
The team of researchers from VCU, Indiana University Medical Center, University of Nebraska Medical Center, University of Arkansas for Medical Sciences, and the University of South Florida, including Carlyon and lead author Chelsea Cockburn, an M.D.-Ph.D. candidate, are the first to investigate the mechanisms by which FIASMAs target multiple intracellular bacteria in detail.
The scientists tested FIASMA susceptibility for four bacterial species that cause human granulocytic anaplasmosis, a tick-borne disease that attacks white blood cells called neutrophils and can be fatal to immune compromised individuals; Q fever, a debilitating pneumonic disease; and two chlamydia infections.
FIASMAs ultimately disrupt how cholesterol, a key nutrient utilized by many intracellular pathogens, traffics inside cells to alter bacterial access to the lipid. The researchers first proved FIASMA treatment efficacy by halting anaplasmosis in both tissue culture and mice. Next, they extended their observations to demonstrate that FIASMA treatment killed the Q fever agent,Coxiella burnetii, and partially inhibited chlamydial infections in cell culture.
“Since FIASMAs influence cholesterol trafficking in the cell and cholesterol plays a role in so many facets of our biology, they have been used to treat a wide variety of conditions and diseases,” Carlyon said.
He added that the effect of FIASMAs on intracellular cholesterol ultimately bypasses the need to directly target the bacteria.
“What is so exciting about this study is that the class of drugs we evaluated targets an enzyme in our cells regulating cholesterol, not the bacteria,” Carlyon said. “I do not envision the pathogens being able to develop resistance to this treatment because it is targeting a host pathway that they very much need to grow and survive inside of the body.”
The Latest on: Alternative to antibiotics
via Google News
The Latest on: Alternative to antibiotics
- Proteon Pharma to Focus on Development of Bacteriophages as a Sustainable Alternative to Antibiotics in Poultry Industryon October 12, 2021 at 3:56 am
Mumbai, Maharashtra, India Proteon Pharmaceuticals India - a subsidiary of Proteon Pharmaceuticals SA Poland, today announced it will focus on the - Report on The Eastern Herald ...
- No Benefit for Longer-Duration Antibiotic Prophylaxis After Limb Salvageon October 8, 2021 at 12:02 pm
There was no benefit with a longer- versus shorter-duration prophylactic antibiotic regimen in reducing surgical site infections after endoprosthetic reconstruction for lower-extremity bone tumors, ...
- First ‘living medicine’ that treats antibiotic-resistant bacteria developed by scientistson October 7, 2021 at 3:25 am
Researchers in Spain have created the world’s first “living medicine” to treat antibiotic-resistant bacteria growing on the surfaces of medical implants. The team at Barcelona’s Centre for Genomic ...
- AB Vista and Avivagen ink supply deal to push antibiotic alternative in three high value feed marketson October 5, 2021 at 6:51 am
AB Vista is to become an exclusive distributor in the US, Brazil and Thailand of a product designed to reduced antibiotic use in poultry, swine, ruminants, and aquaculture.
- Micreos lands $37M to show whether antibiotic alternative delivers in the clinicon October 1, 2021 at 5:05 am
Investors have bought into Micreos’ vision for a sustainable alternative to antibiotics. With backers putting up 32 million euros ($37 million), Micreos is now poised to show whether its platform can ...
- Micreos secures €32 million for its endolysin-based platform as sustainable alternative to antibioticson September 30, 2021 at 7:33 am
Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria.
- Global Eubiotics Market Outlook 2021-2028: Eubiotics as An Alternative to Antibiotics - ResearchAndMarkets.comon September 30, 2021 at 3:49 am
The "Global Eubiotics Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global eubiotics market is forecast to advance at a CAGR of 7.43% over the registered period ...
- Micreos secures ?32 million for its endolysin-based platform as sustainable alternative to antibioticson September 30, 2021 at 12:39 am
Dutch biotechnology company Micreos announced it has secured another ?32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria.
via Bing News